Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MED28P2 is a genomic region classified as a pseudogene due to its resemblance to the Mediator complex subunit 28 (MED28) gene but lacking an intact protein-coding sequence[1]. Pseudogenes result from gene duplication or retrotransposition events followed by loss of function; while some pseudogenes can influence gene regulatory networks via RNA interference or as competitive endogenous RNAs, there is currently no evidence that MED28P2 has such roles[1][2][3]. It is not a therapeutic target, receptor, enzyme, or transporter and does not produce a protein product. Pseudogenes generally have no function but may occasionally have roles in genome evolution or regulation, as described for other specific cases in the literature[2][3]. In summary, MED28P2 is not a canonical therapeutic target, and its classification as a pseudogene means it lacks the functional attributes required for drug development, disease association, or use as a biomarker[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mediator complex subunit 28 pseudogene 2 (MED28P2).